https://prtimes.jp/main/html/rd/p/000000010.000088821.html

InnoJin Co., Ltd. (Head Office: Bunkyo-ku, Tokyo; Representative Director: Takenori Inomata), a venture company originating from Juntendo University, has raised 220 million yen through a third-party allotment of new shares in its seed round and subsequent Series A round, with Sumitomo Corporation, Nippon Chemiphar Co., Ltd., SEED Co., Ltd., and JINS HOLDINGS Inc. as the primary underwriters.

Based on the funds raised this time, we will further accelerate the development of products and platforms to bring the medical research achievements we have built to practical social implementation. Furthermore, together with our investment partner companies and other healthcare-related companies, we will formulate exit strategies for smooth market entry and work to deliver solutions more quickly to a greater number of patients and healthcare professionals.